Migraine treatments including isovaleramide compounds and...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/00 (2006.01)

Patent

CA 2545771

A method of treating a migraine headache comprising administering at least one serotonin agonist and isovaleramide, .alpha.-methyl isovaleramide, or mixtures thereof to a patient suffering from a migraine. The at least one serotonin agonist is selected from the group consisting of sumatriptan, eleptriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, ergotamine, an ergotamine derivative, and mixtures thereof. A migraine treatment is also provided.

La présente invention a trait à un procédé de traitement de la céphalée migraineuse comprenant l'administration d'au moins un agoniste de la sérotonine et de l'isovaléramide, de méthyle .alpha.' isovaléramide, ou des mélanges de ceux-ci à un patient souffrant de la migraine. Ledit au moins un agoniste de la sérotonine est choisi parmi le groupe constitué de sumatriptan, eleptriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, ergotamine, un dérivé d'ergotamine, et des mélanges de ceux-ci. L'invention a également trait à un traitement de la migraine.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Migraine treatments including isovaleramide compounds and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Migraine treatments including isovaleramide compounds and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Migraine treatments including isovaleramide compounds and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1902487

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.